Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04331639 · ClinicalTrials.gov registry record

High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

A clinical trial of Ulcerative Colitis and Crohn Disease, sponsored by Boston Children's Hospital.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT04331639: Recruiting study of Ulcerative Colitis and Crohn Disease, sponsored by Boston Children's Hospital.

NCT04331639 is a study of Ulcerative Colitis and Crohn Disease that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 50 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04331639, a study of Ulcerative Colitis and Crohn Disease, is actively recruiting participants, sponsored by Boston Children's Hospital.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.

Primary Outcome

assessment of the percentage of patients achieving a serum 25-OHD level in the range of 40-60 ng/mL

Interventions

  • DIETARY_SUPPLEMENT vitamin D3

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2020-11-01
Est. Completion 2025-12-31
Boston Children's Hospital

462 total trials

What NCT04331639 shows while recruiting

NCT04331639 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower).

The record links to 4 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which vitamin D3 is the first listed.

NCT04331639 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04331639 about?

NCT04331639 is a clinical study titled "High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy". The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.

What is the current status of trial NCT04331639?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2020-11-01. Estimated completion is 2025-12-31.

What conditions does trial NCT04331639 study?

This clinical trial studies the following conditions: Ulcerative Colitis, Crohn Disease, Vitamin D Deficiency, Inflammatory Bowel Disease.

What interventions are being tested in trial NCT04331639?

The interventions under investigation include: vitamin D3 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04331639?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04331639 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04331639's enrollment target sits among peer trials

50 87th of 122 higher than 35 of 122 other Ulcerative Colitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04331639, the US trial registry maintained by the National Library of Medicine. NCT04331639 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.